PsA/SpA
Date |
Type | Title | Save |
|---|---|---|---|
| 20 Nov 2019 | ACR Video | Pearls for Evaluating PsA Patients: Dr. Guillermo Valenzuela | |
| 20 Nov 2019 | ACR Video | Tofacitinib as Monotherapy Following MTX Withdrawal in PsA: Dr. Eric Ruderman | |
| 18 Nov 2019 | ACR Video | Non-radiographic axSpA: Dr. Philip Robinson | |
| 18 Nov 2019 | ACR Video | Highlights of AS, Psoriatic Arthritis Studies: Dr. Lianne Gensler | |
| 18 Nov 2019 | ACR Video | Inflammatory Back Pain in axSpA: Dr. Rachel Tate | |
| 18 Nov 2019 | ACR Video | Psoriatic Arthritis and Guselkumab: Dr. Eric Ruderman | |
| 18 Nov 2019 | News | New Treatments in Axial SpA from #ACR2019 | |
| 13 Nov 2019 | Social | #ACR19 Rheumatology RoundUp - Kavanaughs Picks: 2505 PsA prevention 1366 Self Joint exams 1120 Rheum burnout 1310 OA Hx 565 Enteropathic arthritis Recs 1823 MRE dx of SI 2773 Machine learning 2772 Antiinflammatory diet in RA 1359 Synovial Bx | |
| 13 Nov 2019 | Social | RT @synovialjoints: Results from2 anti-IL-17 agents Secukinumab and Ixekizumab in non-radiographic axial Spondyloarthritis poster #L2 and a… | |
| 13 Nov 2019 | Social | RT @synovialjoints: The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected… | |
| 13 Nov 2019 | Social | RT @synovialjoints: PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs… | |
| 13 Nov 2019 | Social | RT @DrKanikaMonga: Abstract #0626 Are there really differences between non-radiographic and radiographic axial spondyloarthritis? Data from… | |
| 13 Nov 2019 | Social | RT @Janetbirdope: Certrolizumab pegol decreases uveitis in open label study of SpA with past uveitis and HLAB27 group enriched for recurren… | |
| 13 Nov 2019 | Social | RT @Janetbirdope: 1/3 of pts using apremilast with PsA/SpA from Corrona data base are using it in combination with bDMARDs. Not sure how th… | |
| 13 Nov 2019 | Social | RT @uptoTate: MAXIMISE results in axial manifestations of PsA. SEC met primary phase 3b ASAS 20 endpoint after inadequate NSAID response. h… | |
| 13 Nov 2019 | ACR Video | Myosin Regulation May Contribute to Anti-TNF Therapy Response: Dr. Elaine Husni | |
| 13 Nov 2019 | Social | RT @uptoTate: Tildrakizumab (TIL), anti–IL-23p19 monoclonal ab, superior to PBO in phase 2b trial results in PsA. https://t.co/i0vIEHD4hx #… | |
| 13 Nov 2019 | Social | RT @uptoTate: Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https:… | |
| 13 Nov 2019 | Social | RT @uptoTate: Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase… | |
| 13 Nov 2019 | Social | RT @uptoTate: Go-DACT proof on concept results: golimumab + MTX superior to monotherapy MTX in PsA dactylitis. https://t.co/dEGnjiuGZf #ACR… |
